CD24-dependent innate immune checkpoint targeting chimera disrupts TGF-β-driven immunosuppression to enhance anti-tumor therapy
The immunosuppressive tumor microenvironment (TME) poses formidable challenges for cancer immunotherapies. Among the complex TME landscape, the cytokine TG